Currently, Mind Medicine Inc [MNMD] is trading at $9.95, up 12.05%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The MNMD shares have gain 19.45% over the last week, with a monthly amount glided 40.34%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Mind Medicine Inc [NASDAQ: MNMD] stock has seen the most recent analyst activity on January 28, 2025, when Evercore ISI initiated its Outperform rating and assigned the stock a price target of $23. Previously, Chardan Capital Markets started tracking the stock with Buy rating on December 20, 2024, and set its price target to $20. ROTH MKM started tracking the stock assigning a Buy rating and suggested a price target of $36 on July 24, 2024. Robert W. Baird initiated its recommendation with a Outperform and recommended $27 as its price target on May 29, 2024. Leerink Partners started tracking with a Outperform rating for this stock on April 15, 2024, and assigned it a price target of $20. In a note dated December 05, 2023, Canaccord Genuity initiated an Buy rating and provided a target price of $9 on this stock.
This stock has fluctuated between a low of $4.70 and a high of $10.44 over the last 52 weeks. Currently, Wall Street analysts expect the stock to reach $16 within the next 12 months. Mind Medicine Inc [NASDAQ: MNMD] shares were valued at $9.95 at the most recent close of the market. An investor can expect a potential return of 60.8% based on the average MNMD price forecast.
Analyzing the MNMD fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.28, Equity is -0.33 and Total Capital is -0.47. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.1.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Mind Medicine Inc [NASDAQ:MNMD] is 7.27. Also, the Quick Ratio is 7.27, while the Cash Ratio stands at 2.72.
Transactions by insiders
Recent insider trading involved Sullivan Mark, Chief Legal Officer, that happened on Jun 25 ’25 when 11491.0 shares were sold. Chief Medical Officer, Karlin Daniel completed a deal on Jun 25 ’25 to sell 7848.0 shares. Meanwhile, Chief Executive Officer Barrow Robert sold 26491.0 shares on Jun 25 ’25.
